Qureight
End-to-end imaging company for clinical trials with a focus on lung and heart disease.
$20MSeries B
Role not disclosedM
Meltwind
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $73M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionIMU Biosciences
Profiles human immune systems using multi-omic analysis and machine learning for disease research.
$53MSeries A
Role not disclosed